Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration

Journal of Ophthalmology

Volumn 2013, Issue , 2013, Pages

  Fang, Kai ^a   Tian, Jun ^a   Qing, Xueying ^a   Li, Shuai ^a   Hou, Jing ^b,c   Li, Juan ^d   Yu, Wenzhen ^b,c   Chen, Dafang ^a   Hu, Yonghua ^a   Li, Xiaoxin ^b,c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d Beijing Municipal Center of Disease Prevention and Control   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884262965     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2013/676049     Document Type: Article

References (42)

1. Congdon N., O'Colmain B., Klaver C. C., Klein R., Muñoz B., Friedman D. S., Kempen J., Taylor H. R., Mitchell P., Causes and prevalence of visual impairment among adults in the United States. Archives of Ophthalmology 2004 122 4 477 485
2. Pascolini D., Mariotti S. P., Pokharel G. P., Pararajasegaram R., Etya'ale D., Négrel A.-D., Resnikoff S., 2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiology 2004 11 2 67 115 2-s2.0-1942500141 10.1076/opep.11.2. 67.28158
3. Ferris F. L. III, Fine S. L., Hyman L., Age-related macular degeneration and blindness due to neovascular maculopathy. Archives of Ophthalmology 1984 102 11 1640 1642 2-s2.0-0021752680
4. Wells J. A., Murthy R., Chibber R., Nunn A., Molinatti P. A., Kohner E. M., Gregor Z. J., Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. British Journal of Ophthalmology 1996 80 4 363 366 2-s2.0-0029935043
5. Wang F., Rendahl K. G., Manning W. C., Quiroz D., Coyne M., Miller S. S., AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Investigative Ophthalmology and Visual Science 2003 44 2 781 790 2-s2.0-0037310001 10.1167/iovs.02-0281
6. Hera R., Keramidas M., Peoc'h M., Mouillon M., Romanet J.-P., Feige J.-J., Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. American Journal of Ophthalmology 2005 139 4 589 596 2-s2.0-17144408416
7. Spilsbury K., Garrett K. L., Shen W.-Y., Constable I. J., Rakoczy P. E., Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. American Journal of Pathology 2000 157 1 135 144 2-s2.0-0033882695
8. Brown D. M., Michels M., Kaiser P. K., Heier J. S., Sy J. P., Ianchulev T., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009 116 1 57 65 2-s2.0-57949094834 10.1016/j.ophtha.2008.10.018
9. Abraham P., Yue H., Wilson L., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. American Journal of Ophthalmology 2010 150 3 315 e1 2-s2.0-77956056292 10.1016/j.ajo.2010.04.011
10. Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J.-F., Schlingemann R. O., Axer-Siegel R., Wiedemann P., Simader C., Gekkieva M., Weichselberger A., Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011 118 5 831 839 2-s2.0-79955631484 10.1016/j.ophtha.2010.09.004
11. Gaudreault J., Fei D., Rusit J., Suboc P., Shiu V., Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Investigative Ophthalmology and Visual Science 2005 46 2 726 733 2-s2.0-13944266313 10.1167/iovs.04-0601
12. Bakri S. J., Snyder M. R., Reid J. M., Pulido J. S., Ezzat M. K., Singh R. J., Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007 114 12 2179 2182 2-s2.0-36549039554 10.1016/j.ophtha.2007.09.012
13. Martin D. F., Maguire M. G., Ying G.-S., Grunwald J. E., Fine S. L., Jaffe G. J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2011 364 20 1897 1908 2-s2.0-79956218863 10.1056/NEJMoa1102673
14. Avery R. L., Pieramici D. J., Rabena M. D., Castellarin A. A., Nasir M. A., Giust M. J., Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006 113 3 363 372 2-s2.0-33644502828 10.1016/j.ophtha.2005.11.019
15. Aisenbrey S., Ziemssen F., Völker M., Gelisken F., Szurman P., Jaissle G., Grisanti S., Bartz-Schmidt K. U., Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2007 245 7 941 948 2-s2.0-34250792237 10.1007/s00417-006-0471-7
16. Bashshur Z. F., Haddad Z. A., Schakal A., Jaafar R. F., Saab M., Noureddin B. N., Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. American Journal of Ophthalmology 2008 145 2 249 e2 2-s2.0-38349122535 10.1016/j.ajo.2007.09.031
17. Bashshur Z. F., Haddad Z. A., Schakal A. R., Jaafar R. F., Saad A., Noureddin B. N., Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. American Journal of Ophthalmology 2009 148 1 59 65 2-s2.0-67149131231 10.1016/j.ajo.2009.02.006
18. Li X., Hu Y., Sun X., Zhang J., Zhang M., Bevacizumab for neovascular age-related macular degeneration in China. Ophthalmology 2012 119 10 2087 2093
19. Boyer D. S., Antoszyk A. N., Awh C. C., Bhisitkul R. B., Shapiro H., Acharya N. R., Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 114 2 246 252 2-s2.0-33846586501 10.1016/j.ophtha.2006.10.045
20. Kaiser P. K., Brown D. M., Zhang K., Hudson H. L., Holz F. G., Shapiro H., Schneider S., Acharya N. R., Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. American Journal of Ophthalmology 2007 144 6 850 857 2-s2.0-36249002808 10.1016/j.ajo.2007.08.012
21. Ying G. S., Huang J., Maguire M. G., Jaffe G. J., Grunwald J. E., Toth C., Daniel E., Klein M., Pieramici D., Wells J., Martin D. F., Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013 120 1 122 129
22. Brantley M. A. Jr., Fang A. M., King J. M., Tewari A., Kymes S. M., Shiels A., Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007 114 12 2168 2173 2-s2.0-36549016602 10.1016/j.ophtha.2007.09.008
23. Imai D., Mori K., Horie-Inoue K., Gehlbach P. L., Awata T., Inoue S., Yoneya S., CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. Journal of Ocular Biology, Diseases, and Informatics 2010 3 2 53 59 2-s2.0-79955796065 10.1007/s12177-010-9055-1
24. Tian J., Qin X., Fang K., Chen Q., Hou J., Li J., Yu W., Chen D., Hu Y., Li X., Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics 2012 13 7 779 787
25. Smith W., Assink J., Klein R., Mitchell P., Klaver C. C. W., Klein B. E. K., Hofman A., Jensen S., Wang J. J., De Jong P. T. V. M., Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001 108 4 697 704 2-s2.0-0035078715 10.1016/S0161-6420(00)00580-7
26. Clemons T. E., Milton R. C., Klein R., Seddon J. M., Ferris F. L. III, Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19. Ophthalmology 2005 112 4 533 539 2-s2.0-16244368037 10.1016/j.ophtha.2004.10.047
27. Khan J. C., Thurlby D. A., Shahid H., Clayton D. G., Yates J. R. W., Bradley M., Moore A. T., Bird A. C., Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. British Journal of Ophthalmology 2006 90 1 75 80 2-s2.0-29744442338 10.1136/bjo.2005.073643
28. Teper S. J., Nowinska A., Pilat J., Palucha A., Wylegala E., Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Molecular Vision 2010 16 2598 2604 2-s2.0-78650767139
29. Orlin A., Hadley D., Chang W., Ho A. C., Brown G., Kaiser R. S., Regillo C. D., Godshalk A. N., Lier A., Kaderli B., Stambolian D., Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012 32 1 4 9 2-s2.0-84855170104 10.1097/IAE.0b013e31822a2c7c
30. Yamashiro K., Tomita K., Tsujikawa A., Nakata I., Akagi-Kurashige Y., Miyake M., Ooto S., Tamura H., Yoshimura N., Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. American Journal of Ophthalmology 2012 154 1 125 136 2-s2.0-84858981567 10.1016/j.ajo.2012.01.010
31. Kloeckener-Gruissem B., Barthelmes D., Labs S., Schindler C., Kurz-Levin M., Michels S., Fleischhauer J., Berger W., Sutter F., Menghini M., Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Investigative ophthalmology & Visual Science 2011 52 7 4694 4702 2-s2.0-80051763854
32. McKibbin M., Ali M., Bansal S., Baxter P. D., West K., Williams G., Cassidy F., Inglehearn C. F., CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. British Journal of Ophthalmology 2012 96 2 208 212 2-s2.0-84856059368 10.1136/bjo.2010.193680
33. Conklin B. S., Zhao W., Zhong D.-S., Chen C., Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. American Journal of Pathology 2002 160 2 413 418 2-s2.0-0036172287
34. Pons M., Marin-Castaño M. E., Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD. Investigative Ophthalmology & Visual Science 2011 52 6 3842 3853 2-s2.0-79957746980
35. Fujihara M., Nagai N., Sussan T. E., Biswal S., Handa J. T., Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigmented epithelial cells in mice. PLoS One 2008 3 9 2-s2.0-52349098746 10.1371/journal.pone.0003119 e3119
36. Bertram K. M., Baglole C. J., Phipps R. P., Libby R. T., Molecular regulation of cigarette smoke induced-oxidative stress in human retinal pigment epithelial cells: implications for age-related macular degeneration. American Journal of Physiology. Cell Physiology 2009 297 5 C1200 C1210 2-s2.0-70449644673 10.1152/ajpcell.00126.2009
37. Pons M., Marin-Castaño M. E., Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigment epithelium in vitro and in vivo. PLoS One 2011 6 2 2-s2.0-79952230345 10.1371/journal.pone. 0016722 e16722
38. Takeuchi A., Takeuchi M., Oikawa K., Sonoda K.-H., Usui Y., Okunuki Y., Takeda A., Oshima Y., Yoshida K., Usui M., Goto H., Kuroda M., Effects of dioxin on vascular endothelial growth factor (VEGF) production in the retina associated with choroidal neovascularization. Investigative Ophthalmology and Visual Science 2009 50 7 3410 3416 2-s2.0-67649946260 10.1167/iovs.08-2299
39. Solberg Y., Rosner M., Belkin M., The association betwen cigarette smoking and ocular diseases. Survey of Ophthalmology 1998 42 6 535 547 2-s2.0-0031595250 10.1016/S0039-6257(98)00002-2
40. Lutty G., Grunwald J., Majji A. B., Uyama M., Yoneya S., Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Molecular Vision 1999 5 article 35 2-s2.0-17144433662
41. Hammond B. R. Jr., Wooten B. R., Snodderly D. M., Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision Research 1996 36 18 3003 3009 2-s2.0-0030249886 10.1016/0042-6989(96)00008-9
42. Hammond B. R. Jr., Caruso-Avery M., Macular pigment optical density in a southwestern sample. Investigative Ophthalmology and Visual Science 2000 41 6 1492 1497 2-s2.0-0034098106